Filing Analysis
Cabaletta Bio, Inc. announced its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Announcement date: August 13, 2026.
- The company furnished a press release as Exhibit 99.1 containing the financial results.
Cabaletta Bio held its Annual Meeting of Stockholders on June 9, 2026, where shareholders approved a significant increase in the number of authorized shares of common stock. The company also elected two Class I directors and ratified its independent auditor.
🚩 Red Flags
- Significant increase in authorized shares (doubling from 300M to 600M) typically signals future dilution through new equity offerings.
📋 Key Facts
- Authorized shares of common stock increased from 300,000,000 to 600,000,000 (a 100% increase).
- The Certificate of Amendment became effective on June 9, 2026.
- Scott Brun, M.D. and Shawn Tomasello, MBA were elected as Class I directors for three-year terms.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Plan Amendment Proposal) was withdrawn by the Board of Directors on May 31, 2026.
Cabaletta Bio issued a press release and updated corporate presentation providing clinical data updates for its rese-cel autoimmune portfolio. The filing highlights positive early findings in lupus, myositis, and systemic sclerosis, including progress toward registrational trials.
📋 Key Facts
- Presented data from 52 evaluable patients across myositis (17), lupus (20), and systemic sclerosis (15).
- RESET-Myositis: 80% (8/10) of DM and ASyS patients would have met the primary endpoint of the registrational cohort.
- RESET-SSc: 83% (5/6) of patients achieved rCRISS-25 and 67% (4/6) achieved rCRISS-50 at 36 weeks while off immunomodulators.
- RESET-SLE: 75% (6/8) of patients with 12 months follow-up achieved Definition of Remission in SLE (DORIS) while remaining off immunomodulators.
- Company plans to initiate a systemic sclerosis (SSc) registrational program in 4Q26.
- Topline data from the DM/ASyS registrational cohort is expected in mid-2027.
- BLA submission strategy for adult DM and JDM is planned for 2H27.
Cabaletta Bio, Inc. announced its financial results for the first quarter ended March 31, 2026, through a press release furnished to the SEC. This is a routine quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- Financial results reported for the first quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cabaletta Bio reported positive early clinical data for its rese-cel therapy in a preconditioning-free cohort of pemphigus vulgaris patients and successfully demonstrated automated manufacturing using the Cellares Cell Shuttle. The data showed that 2 of 4 patients achieved drug-free clinical responses at 6 months without the need for chemotherapy preconditioning.
📋 Key Facts
- Reported clinical and translational data from 4 patients in the RESET-PV trial treated with rese-cel without preconditioning (PC-free).
- 2 of 4 patients maintained drug-free clinical responses through 24 weeks of follow-up at the lowest dose.
- Safety profile showed no dose-limiting toxicities (DLT) or ICANS, with only one patient experiencing Grade 1 cytokine release syndrome (CRS).
- First clinical use of the Cellares Cell Shuttle for automated manufacturing, with the first two doses meeting all release specifications.
- Anticipated data for higher doses of PC-free rese-cel in PV expected in 2H26; initial SLE data expected in 1H26 (June 2026).
Cabaletta Bio announced an underwritten registered direct offering of 51.7 million shares at $2.90 per share, expected to yield approximately $141 million in net proceeds. The company also provided a preliminary Q1 2026 cash balance of $117 million and updated its cash runway guidance to mid-2027.
🚩 Red Flags
- Significant equity dilution resulting from the issuance of 51.7 million new shares.
- Relatively short cash runway extension, only reaching mid-2027 despite the $141 million raise.
📋 Key Facts
- Offering of 51,725,000 shares of common stock at a price of $2.90 per share.
- Net proceeds estimated at approximately $141 million after fees.
- Preliminary cash and cash equivalents of $117 million as of March 31, 2026.
- Proceeds intended for clinical development of rese-cel, including a myositis registrational study.
- Cash runway expected to extend into mid-2027.
- Underwriters include TD Securities (USA) LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co.
Cabaletta Bio reported positive initial clinical data from four refractory patients in its RESET-PV trial evaluating rese-cel without preconditioning. The data showed clear biologic activity and a favorable safety profile at the lowest dose, with three of four patients remaining off immunomodulators and steroids.
📋 Key Facts
- Clinical data presented for 4 refractory patients in the RESET-PV (pemphigus vulgaris) trial.
- The trial evaluates rese-cel without the use of cyclophosphamide and fludarabine as preconditioning agents.
- 3 of 4 patients remained off all immunomodulators and steroids as of the April 2, 2026 data cut-off.
- Complete peripheral B cell elimination was observed in 3 of 4 patients.
- Safety profile: 1 patient with Grade 1 cytokine release syndrome (CRS); no ICANS observed.
- Higher dose cohorts have been enrolled with durability data anticipated in the second half of 2026.
Cabaletta Bio, Inc. has updated its corporate presentation as of April 20, 2026, and made it available on the company's website. The presentation is included as Exhibit 99.1 in this filing for public disclosure.
📋 Key Facts
- Updated corporate presentation released on April 20, 2026.
- The presentation was filed as Exhibit 99.1 under Item 8.01 (Other Events).
- The filing was signed by CEO Steven Nichtberger.
Cabaletta Bio reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company also released an updated corporate presentation for investors.
📋 Key Facts
- Financial results for the fiscal year ended December 31, 2025, were announced on March 23, 2026.
- An updated corporate presentation was posted to the company's website and filed as Exhibit 99.2.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Cabaletta Bio issued a press release outlining its 2026 strategic priorities, focusing on advancing its lead CAR T therapy, rese-cel, through registrational cohorts for multiple autoimmune diseases and implementing automated manufacturing technologies.
🚩 Red Flags
- High clinical trial dependency: Success is heavily contingent on upcoming 1H26 data readouts for multiple indications.
📋 Key Facts
- Initiated FDA-aligned dermatomyositis (DM) and antisynthetase syndrome (ASyS) registrational cohort in December 2025; aiming for BLA submission in 2027.
- Received RMAT designation from the FDA for rese-cel in the treatment of systemic sclerosis.
- Aligned with the FDA on registrational cohort designs for SLE and LN (Lupus Nephritis) using a single-infusion, weight-based dose.
- Obtained IND amendment clearance to use Cellares Cell Shuttle for automated manufacturing of rese-cel, marking a first for autologous CAR T programs.
- Anticipates complete Phase 1/2 data readouts across three RESET trials (SLE, SSc, and MG) in the first half of 2026.
Cabaletta Bio, Inc. announced its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025
- Report date: November 10, 2025
- The company furnished a press release (Exhibit 99.1) containing the financial results.
Cabaletta Bio, Inc. filed an 8-K to announce the release of an updated corporate presentation on its website. The filing serves as a formal notice that the company's investor relations materials have been refreshed.
📋 Key Facts
- The Company posted an updated Corporate Presentation to its website on October 29, 2025.
- The update is located in the 'Investors & Media' section of www.cabalettabio.com.
- The presentation is attached as Exhibit 99.1.
Cabaletta Bio issued a press release and updated corporate presentation detailing new clinical data for its cell therapy, rese-cel, across multiple autoimmune disease trials (Myositis, SSc, and SLE). The company reported positive efficacy signals in several cohorts and announced plans to initiate registrational cohorts or expand trial designs based on these results.
🚩 Red Flags
- One grade 3 ICANS event reported in the SSc cohort (previously disclosed).
📋 Key Facts
- RESET-Myositis: 4 of 13 patients experienced grade 1 CRS; no ICANS observed. All 4 DM/ASyS patients met key inclusion criteria for the registrational cohort and achieved moderate or major TIS responses at week 16.
- RESET-SSc: Preliminary data from 6 patients showed 4 patients achieved rCRISS-25 response off immunomodulators and steroids; one grade 3 ICANS event was reported (previously disclosed in March 2025).
- RESET-SLE: 9 patients evaluated; 8 of 9 experienced no ICANS. Three of four SLE patients achieved DORIS remission, and three of four LN patients showed renal response.
- Company is initiating a DM/ASyS registrational cohort in the RESET-Myositis trial this quarter.
- Cabaletta is expanding its 'no preconditioning' dosing strategy into the SLE trial, with data expected in 2026.
Cabaletta Bio, Inc. released new clinical and translational data from its RESET-PV trial evaluating rese-cel (resecabtagene autoleucel) in patients with Pemphigus Vulgaris. The data shows meaningful early clinical responses and a manageable safety profile without ICANS reported.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Data cut-off date: September 11, 2025.
- Trial focus: Evaluating rese-cel without the use of cyclophosphamide and fludarabine as preconditioning agents.
- Clinical results: All three evaluable patients showed meaningful early clinical responses (PDAI score improvement) starting in the first month post-infusion.
- Patient 1 PDAI: Improved from 24 to 10 at 4 months.
- Patient 2 PDAI: Improved from 83 to 3 at 3 months.
- Patient 3 PDAI: Improved from 22 to 2 at 1 month.
- Safety: No ICANS reported; Patient 1 had Grade 1 CRS (transient fever); Patient 2 required a steroid course for a disease flare but has since tapered below baseline.
- Translational data: Patients showed substantial B cell depletion, with patients 2 and 3 achieving complete peripheral B cell depletion.
Cabaletta Bio, Inc. has filed an 8-K to furnish an updated corporate presentation via its website under Regulation FD disclosure.
📋 Key Facts
- The company posted an updated Corporate Presentation (Exhibit 99.1) to its website on September 3, 2025.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Cabaletta Bio, Inc. announced its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Announcement date: August 7, 2025.
- The company furnished results under Item 2.02 of Form 8-K.
Cabaletta Bio, Inc. entered into an underwriting agreement to conduct a large-scale underwritten offering of common stock and warrants. The company intends to use the proceeds, totaling approximately $94M–$108.1M, to fund clinical development and manufacturing for its lead candidate, rese-cel.
🚩 Red Flags
- Significant dilution: The issuance of up to 50 million warrants and over 10 million pre-funded warrants represents substantial potential future dilution for existing shareholders.
- Warrant pricing: Common stock warrants are priced at $2.50, which is a premium to the current offering price of $2.00, but the sheer volume of warrants issued is high.
📋 Key Facts
- Offering includes 39,200,000 shares of common stock and 50,000,000 Common Stock Warrants.
- Includes 10,800,000 Pre-Funded Warrants to certain investors.
- Underwriters include Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co.
- Combined offering price for common stock/warrant is $2.00 per share; pre-funded warrants at $1.99999.
- Common Stock Warrants have an exercise price of $2.50 and expire in 15 months.
- Estimated net proceeds: ~$94 million (excluding over-allotment) to ~$108.1 million (including over-allotment).
- Proceeds intended for clinical development of rese-cel, manufacturing expansion, and working capital.
- Company expects proceeds + existing cash to fund operations into the second half of 2026.
Cabaletta Bio has mutually terminated its $200 million At-the-Market (ATM) sales agreement with TD Cowen, effective June 11, 2025. Simultaneously, the company released positive clinical data from its RESET trial programs for rese-cel.
🚩 Red Flags
- Termination of a significant $200M liquidity tool (ATM program) may limit immediate capital raising capacity through this specific mechanism.
📋 Key Facts
- Termination of Sales Agreement with TD Securities (USA) LLC (TD Cowen) effective June 11, 2025.
- Prior to termination, $7.88 million in gross proceeds were raised via the ATM program.
- $192.12 million in remaining capacity under the ATM agreement will no longer be available for sale.
- Released clinical data from RESET-Myositis, RESET-SLE, and RESET-SSc trials involving 18 evaluable patients.
- Reported high safety profile: 94% of patients experienced no CRS or only Grade 1 CRS; 89% had no ICANS.
Cabaletta Bio held its Annual Meeting of Stockholders on June 9, 2025, where shareholders approved a significant increase in authorized common stock. The company also elected two directors and ratified Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Doubling of authorized share count (from 150M to 300M) creates significant potential for future dilution via secondary offerings or warrants.
📋 Key Facts
- Stockholders approved an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
- Elected Steven Nichtberger, M.D. and Mark Simon, MBA as Class III directors for three-year terms expiring in 2028.
- Ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Approved non-binding advisory compensation (Say-on-Pay) for named executive officers.
- Voted to hold future advisory votes on executive compensation on an annual basis.
Cabaletta Bio, Inc. has approved a repricing of stock options for certain employees, executive officers, and directors because approximately 75% of their options were 'underwater.' The new exercise price is set at $1.92, subject to a one-year retention period.
🚩 Red Flags
- Option repricing (repricing of underwater options) can be viewed as a dilution-related signal that management is attempting to realign incentives after significant share price decline.
- The repricing includes executive officers and directors, which can raise concerns regarding alignment with shareholder interests during periods of poor stock performance.
📋 Key Facts
- Board approval date: May 15, 2025; Effective Date: May 19, 2025.
- Approximately 75% of stock options held by employees and directors were 'underwater' (exercise price > current market price).
- New exercise price for Eligible Options is $1.92.
- Repricing applies to options with an original exercise price in excess of 1.5x the closing price on May 19, 2025.
- Eligible Participants include CEO Steven Nichtberger, CFO Anup Marda, and several directors/consultants.
- A 'Retention Period' is required: participants must remain with the company for at least one year from the Effective Date to keep the new price.
Cabaletta Bio disclosed its quarterly cash position as of March 31, 2025, noting a decrease in liquidity and providing an updated runway estimate. The company also announced regulatory alignment regarding its BLA submission timeline for Rese-cel.
🚩 Red Flags
- Cash position decreased by $32.2 million over the first quarter of 2025.
- Burn rate suggests a need for capital or significant revenue/milestone events before H2 2026.
📋 Key Facts
- Cash and cash equivalents as of March 31, 2025: $131.8 million.
- Cash and cash equivalents as of December 31, 2024: $164.0 million.
- Expected cash runway extends into the first half of 2026.
- Company announced anticipated 2027 BLA submission for Rese-cel in Myositis following FDA alignment on registrational cohorts.
Cabaletta Bio, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Cabaletta Bio filed an 8-K/A (Amendment No. 1) to clarify clinical data regarding its RESET-Myositis trial. The amendment specifies that as of the January 8, 2025 data cut-off, the first adult dermatomyositis patient was off all immunosuppressants and tapering steroids.
🚩 Red Flags
- Amendment to a previous filing (8-K/A) can sometimes indicate errors in initial data reporting or communication.
📋 Key Facts
- Amendment (8-K/A) filed on February 18, 2025, to correct/clarify an earlier filing.
- Clarification regarding the RESET-Myositis trial: first adult dermatomyositis patient was off all immunosuppressants and tapering steroids as of Jan 8, 2025.
- Revised corporate presentation and press release were issued to reflect this clinical update.
Cabaletta Bio issued an 8-K to provide updated clinical data from the first 10 patients dosed with its lead candidate, resecabtagene autoleucel (rese-cel), across its RESET clinical development program. The data highlights positive safety and efficacy signals in autoimmune disease cohorts including SLE, myositis, and systemic sclerosis.
🚩 Red Flags
- Clinical data is based on a very small sample size (n=10) which carries inherent volatility in outcomes.
- The company's future success is heavily dependent on the successful completion of ongoing Phase 1/2 trials and regulatory pathways.
📋 Key Facts
- Clinical update covers the first 10 patients dosed with rese-cel as of a January 8, 2025, data cut-off.
- In the RESET-SLE trial, 3 out of 4 non-renal SLE patients achieved DORIS remission; one lupus nephritis patient achieved complete renal response (CRR).
- All 6 SLE and LN patients demonstrated clinical responses off all immunosuppressants and steroids.
- 90% of patients experienced either no or only Grade 1 Cytokine Release Syndrome (CRS); 90% experienced no immune effector cell-associated neurotoxicity syndrome (ICANS).
- In the RESET-Myositis trial, one adult dermatomyositis patient maintained major total improvement score (TIS) at 3 months post-infusion while off all steroids/immunosuppressants.
- The company is evaluating rese-cel across rheumatology, neurology, and dermatology via six Phase 1/2 clinical trials.
Cabaletta Bio disclosed its year-end 2024 cash position of $164 million, stating this provides a runway into the first half of 2026. The company also provided updates on clinical pipeline progress for its rese-cel therapy and strategic milestones for 2025.
🚩 Red Flags
- Financials are unaudited and preliminary; audit is ongoing and could result in changes.
📋 Key Facts
- Unaudited cash and cash equivalents as of Dec 31, 2024: $164 million.
- Cash runway expected to extend into the first half of 2026.
- Expanded CDMO agreement with Lonza to supply rese-cel clinical product starting H2 2025.
- FDA granted Fast Track Designation for rese-cel in relapsing and progressive MS.
- 90% of the first 10 patients dosed with rese-cel (with 1-month follow-up) experienced either no CRS or only Grade 1 CRS, and 90% experienced no ICANS.
Cabaletta Bio released updated clinical data for its CABA-201 CAR T cell therapy at the ACR Convergence 2024 conference. The data from eight patients across Myositis, SLE, and SSc trials showed favorable safety profiles and early signs of efficacy, including potential drug-free clinical responses.
🚩 Red Flags
- None identified in this clinical update filing.
📋 Key Facts
- Updated clinical data presented for CABA-201 in Phase 1/2 RESET clinical development program (Myositis, SLE, and SSc).
- Eight patients were evaluable as of the November 1, 2024, data cut-off date.
- Safety: No evidence of ICANS observed since August 2024; low-grade CRS (Grades 1-2) observed in 3 of 8 patients, all recovering with standard care.
- Efficacy: All four patients in the RESET-SLE trial demonstrated clinical responses off immunosuppressants.
- Translational data showed complete B cell depletion by day 22 post-infusion and early naïve B cell repopulation.
- Clinical outcomes included improved muscle strength in a DM patient and significant reduction in proteinuria in an LN patient.
Cabaletta Bio, Inc. announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal notice of the earnings release furnished via Exhibit 99.1.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024.
- Announcement date: November 14, 2024.
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Cabaletta Bio issued an updated corporate presentation via Regulation FD disclosure to provide clarity on upcoming clinical data milestones. The company highlighted specific timelines for data readouts from its RESET program trials.
📋 Key Facts
- Updated corporate presentation posted to the company website on October 7, 2024.
- Clinical data from RESET-SLE and RESET-Myositis trials, plus initial data from RESET-SSc trial, to be presented at the American College of Rheumatology Convergence 2024 Meeting in November 2024.
- Initial clinical data from the RESET-MG trial is anticipated in the first half of 2025.
Cabaletta Bio entered into a Lease Amendment with CIC Innovation Communities, LLC to revise payment obligations and termination rights for its office and laboratory space. The amendment introduces a lock-in period through August 31, 2026, in exchange for monthly rental discounts.
🚩 Red Flags
- The lease amendment imposes a non-termination period (lock-in) until August 2026, reducing operational flexibility regarding real estate footprint.
📋 Key Facts
- Effective date of Lease Amendment: October 1, 2024.
- The amendment modifies an existing service agreement dated February 1, 2019 (amended Dec 1, 2021).
- New lock-in period: Neither party may terminate the lease from Oct 1, 2024, through Aug 31, 2026.
- Termination notice periods: 30 days for office space; 90 days for laboratory space (subject to the lock-in).
- Aggregate rent for the Premises is approximately $240,000 per month.
- Total aggregate rent over the Initial Term is approximately $5.5 million.
- Includes options for two additional 18-month extension terms.
Cabaletta Bio, Inc. announced its financial results for the second quarter ended June 30, 2024, and updated its corporate presentation.
📋 Key Facts
- Reported Q2 2024 financial results on August 8, 2024.
- Released an updated Corporate Presentation via the company website.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Cabaletta Bio reported positive initial clinical data from the first two patients dosed with CABA-201 in its Phase 1/2 RESET-Myositis and RESET-SLE trials. The data showed favorable safety profiles and early signs of B cell depletion and disease activity improvement.
🚩 Red Flags
- Clinical trials are in early Phase 1/2 stages with very small sample sizes (n=2 reported here) and long-term efficacy remains unproven.
📋 Key Facts
- Reported positive initial clinical data for the first two patients dosed with CABA-201 in Phase 1/2 RESET-Myositis and RESET-SLE trials.
- Safety: No serious adverse events (SAEs) reported; no Cytokine Release Syndrome (CRS) or ICANS observed in either patient.
- IMNM Patient (RESET-Myositis): Completed 3 months of follow-up; showed decline in creatinine kinase from 617 to 308 and a Total Improvement Score (TIS) of 30 at week 12.
- SLE Patient (RESET-SLE): Completed 1 month of follow-up; demonstrated improvement in SLEDAI-2K score from 26 (baseline) to 10 at week 4.
- Both patients achieved complete B cell depletion within 15 days post-infusion.
Cabaletta Bio, Inc. held its 2024 Annual Meeting of Stockholders on June 3, 2024. The meeting resulted in the successful election of two Class II directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 3, 2024.
- Election of Catherine Bollard, MBChB, M.D. to the Board (Class II) approved with 26,225,488 votes in favor.
- Election of Richard Henriques, MBA to the Board (Class II) approved with 37,806,806 votes in favor.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024, approved with 41,355,429 votes in favor.
Cabaletta Bio, Inc. announced its financial results for the first quarter ended March 31, 2024, and updated its corporate presentation.
📋 Key Facts
- Reported Q1 2024 financial results (ended March 31, 2024) via press release.
- Updated Corporate Presentation was posted to the company's website on May 15, 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Cabaletta Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Announcement date: March 21, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the financial results.
Cabaletta Bio announced that the U.S. FDA has granted Orphan Drug Designation to its investigational therapy, CABA-201, for the treatment of systemic sclerosis (SSc). This designation is a regulatory milestone intended to support the development and potential commercialization of the CD19-CAR T cell therapy.
📋 Key Facts
- FDA granted Orphan Drug Designation for CABA-201 on March 20, 2024.
- CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy.
- The designation is specifically for the treatment of systemic sclerosis (SSc).
Cabaletta Bio announced that the FDA has granted Orphan Drug Designation to its investigational therapy, CABA-201, for the treatment of idiopathic inflammatory myopathies (IIM/myositis). This designation supports the company's CARTA strategy to develop cellular therapies for autoimmune diseases.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- FDA granted Orphan Drug Designation for CABA-201 in treating idiopathic inflammatory myopathies (IIM, or myositis) on February 1, 2024.
- CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy.
- The company is conducting four Phase 1/2 RESET™ trials for CABA-201 across multiple autoimmune conditions.
- FDA has cleared IND applications for CABA-201 in SLE, myositis, SSc, and gMG.
- The target patient population for the specific IIM indication includes approximately 66,000 patients in the US.
Cabaletta Bio reported a strong cash position of $241 million as of December 31, 2023, bolstered by significant proceeds from an ATM program. The company also announced FDA Fast Track Designations for its CABA-201 therapy and provided updates on clinical trial timelines.
🚩 Red Flags
- None identified; cash position is robust for a micro-cap biotech.
📋 Key Facts
- Cash, cash equivalents, and short-term investments totaled $241 million as of Dec 31, 2023.
- Sold 4,760,899 shares via ATM program in Q4 2023, generating ~$94.1 million in gross proceeds at an average price of $19.76/share.
- FDA granted Fast Track Designation for CABA-201 for dermatomyositis and systemic sclerosis (SSc).
- Anticipates reporting clinical efficacy/tolerability data for SLE and myositis in H1 2024, and SSc and gMG in H2 2024.
- Cash runway is expected to extend into the first half of 2026.